Tags : ustekinumab


Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement

Shots: Bio-Thera to receive $20M up front and $130M as development and commercial milestones and will be responsible for the development, manufacturing, and supply of BAT2206 Hikma get exclusive rights to commercialize the biosimilar in the US and received first-right-to-negotiate to add Europe (excluding CIS countries) BAT2206 is a mAb, that is a proposed biosimilar […]Read More